Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Myriad Genetics Jumped 21.7% in September

By Maxx Chatsko - Oct 7, 2019 at 1:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The genetic-testing stock can't seem to escape the trap of volatility.

What happened

Shares of Myriad Genetics (MYGN -2.80%) gained nearly 22% last month, according to data provided by S&P Global Market Intelligence. While several genetic-testing peers saw their stock prices decline by double digits in September, the pioneering developer of DNA diagnostics enjoyed a bounce thanks largely to an awful end to August.

The year-to-date stock chart for Myriad Genetics resembles a city skyline -- complete with zigs and zags, abrupt rises, and equally abrupt drops. Things got a little weird in August when the company quietly announced that a major insurer would cover an important test. Shares popped over 50% that day, but gave up all of that and more when investors realized the test in question has drawn significant scrutiny from the U.S. Food and Drug Administration (FDA).

Unfortunately, September's rise doesn't alleviate those concerns for investors, who remain hesitant. Shares of Myriad Genetics have gained just 0.4% from the beginning of the year through the first week of October.

An arrow jumping up shelves on a wall

Image source: Getty Images.

So what

Myriad Genetics has big plans for its GeneSight Psychotropic Test, which matches patients with major depressive disorder or anxiety to the medications most likely to be effective for each individual. But the test didn't demonstrate statistical significance in a clinical trial, and it costs $2,000.

That originally led Wall Street to sour on the product's potential. Would insurance companies really cover it? The surprise disclosure that UnitedHealth would cover the GeneSight Psychotropic test forced analysts to abruptly reconsider their position.

But Wall Street wasn't the only one balking at the value proposition of the GeneSight product. The FDA has been caught off guard by the proliferation of genetic-testing products and services, but has moved quickly to make up for lost time. Regulators have asked several genetic-testing providers, including Myriad Genetics, to alter marketing language when claims made for tests, including GeneSight, aren't supported by clinical evidence.

Now what

To be blunt, investors are still in the maelstrom, which makes it difficult to know how things will shake out for the GeneSight Psychotropic test. It's possible that more insurers pick up coverage of the product. But it's also possible that insurers balk at covering it and doctors hesitate to order it with watered-down claims. Given the company's low margins, it may be best for investors on the prowl for growth stocks to sit on the sidelines when it comes to Myriad Genetics.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Myriad Genetics, Inc. Stock Quote
Myriad Genetics, Inc.
MYGN
$26.70 (-2.80%) $0.77

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.